Managing Hyponatraemia in Lung Cancer

Expert Consensus Recommendations

This meeting is organised and funded by Otsuka Pharmaceutical Europe Ltd.

Sunday, 7th May 2017
Palexpo, Geneva, 18:40 – 19:40, Room A

Dear Colleagues,

Our symposium “Managing Hyponatraemia in Lung Cancer Expert Consensus Recommendations” will consider the wider value of hyponatraemia and SIADH management in lung cancer and the impact that can be made in effective treatment. SIADH and hyponatraemia in lung cancer patients, if not diagnosed and treated, may negatively impact outcomes.

Professor Rossana Berardi and Professor Marcus Säemann, aim to discuss the need of these lung cancer patients and review the most recent data publications on targeted therapies. Alongside sharing personal experiences in their clinics, the esteemed faculty will look at how best to identify these patients, with the aim to challenge current treatment practice.

Finally, they will look at how to help improve patient treatment, improve patient outcomes and provide a combined recommendation on how to manage hyponatraemia in lung cancer.

Throughout the symposium, audience interaction, participation and questions are encouraged.

We look forward to welcoming you to the symposium.

Otsuka Pharmaceutical Europe Ltd

Programme

18:40 Welcome and introduction
Professor Rossana Berardi, Italy

18:45 Hyponatraemia in the oncology patient
Professor Rossana Berardi

19:00 Management, diagnosis and treatment of the oncology patient with hyponatraemia
Professor Marcus Säemann, Austria

19:15 Clinical scenarios – an interactive session
Professor Rossana Berardi;
Professor Marcus Säemann

19:35 Questions, summary and meeting close
Professor Rossana Berardi